Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

Autor: Dominique Berton, Anne Floquet, Willy Lescaut, Gabriel Baron, Marie-Christine Kaminsky, Philippe Toussaint, Rémy Largillier, Aude-Marie Savoye, Jérôme Alexandre, Catherine Delbaldo, Emmanuelle Malaurie, Hugues Barletta, Claire Bosacki, Claire Garnier-Tixidre, Philippe Follana, Hortense Laharie-Mineur, Charles Briac Levache, Bruno Valenza, Agnès Dechartres, Delphine Mollon-Grange, Frédéric Selle

Publikováno v: Frontiers in Pharmacology, Vol 12 (2021)

Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study as

Externí odkaz: https://doaj.org/article/759e5d59f76b40d9ba13a0b2c9ebd372

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

Autor: E. Malaurie, Claire Bosacki, Aude-Marie Savoye, Claire Garnier-Tixidre, Philippe Toussaint, Agnès Dechartres, Rémy Largillier, Gabriel Baron, Marie-Christine Kaminsky, Dominique Berton, Bruno Valenza, Willy Lescaut, Hortense Laharie-Mineur, Jérôme Alexandre, Anne Floquet, Frédéric Selle, Charles Briac Levache, Hugues Barletta, Philippe Follana, Delphine Mollon-Grange, Catherine Delbaldo

Publikováno v: Frontiers in Pharmacology
Frontiers in Pharmacology, Frontiers, 2021, 12, ⟨10.3389/fphar.2021.711813⟩
Frontiers in Pharmacology, Vol 12 (2021)

Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cf7a8cd1710e52fe5eebb4d3d33d65f
https://pubmed.ncbi.nlm.nih.gov/34616296

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Nous devons respecter le schéma vaccinal anti-SARS-CoV-2 sans décalage chez les patients atteints de cancer sous traitement

Autor: Thomas Cluzeau, Olivier Castelnau, Jérôme Barrière, Richard Skaf, J. F. Berdah, Michel Carles, Delphine Borchiellini, Frederic Peyrade, Eric Francois, Clarisse Audigier-Valette, Willy Lescaut, Lauris Gastaud, Wislez Marie, Benjamin Hoch, Ophelie Cassuto

Publikováno v: Bulletin du Cancer. 108:341-342

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ea8219530c9119914073b8b0e501a88
https://doi.org/10.1016/j.bulcan.2021.02.003

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

Autor: Marie J Chammas, Emily Pesek, Robert J. Soiffer, Veronika Bachanova, Abraham Avigdor, Joseph H. Antin, Armando Santoro, Philippe Armand, Willy Lescaut, Anne Thiebaut-Bertrand, Stephen M. Ansell, Jerome Ritz, Pier Luigi Zinzani, Reid W. Merryman, Ahmad Halwani, Miguel-Angel Perales, Scott C. Bresler, Harim Kim, L. Castagna, Amitabh Srivastava, Vincent T. Ho, Haesook T. Kim, Roch Houot, Aspasia Stamatoullas-Bastard, Carol Reynolds, Pierre-Simon Rohrlich, Carmelo Carlo-Stella, Nathalie Dhedin, Hélène Labussière Wallet, Tony Marchand, Sylvie François

Publikováno v: Blood
Blood, American Society of Hematology, 2017, 129 (10), pp.1380-1388. ⟨10.1182/blood-2016-09-738385⟩
Blood, 2017, 129 (10), pp.1380-1388. ⟨10.1182/blood-2016-09-738385⟩

International audience; Anti-programmed cell death protein 1 (PD-1) monoclonal antibodies are being increasingly tested in patients with advanced lymphoma. Following treatment, many of those patients are likely to be candidates for allogeneic hematop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be36b519c34b9ebc42d3160174216b3
https://europepmc.org/articles/PMC5345733/